Sodium dichloroacetate is under clinical development by Saol Therapeutics and currently in Phase III for Neurometabolic Disease. According to GlobalData, Phase III drugs for Neurometabolic Disease have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Sodium dichloroacetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sodium dichloroacetate overview
Sodium dichloroacetate is under development for the treatment of pyruvate dehydrogenase complex deficiency, glioblastoma multiforme, rare pediatric solid tumors including wilms, neuroblastoma, rhabdoid tumor, osteosarcoma, ewing Sarcoma, and rhabdomyosarcoma. It is administered through oral route. It acts by targeting PDHA1.
Saol Therapeutics overview
Saol Therapeutics (Saol) is a pharmaceutical company that develops and manufactures therapeutic products for neuroscience and other rare diseases. The company offers pipeline products such as SL – 1002, and SL – 1009 and its targeted areas of research include pain related to Osteoarthritis (OA) of the Knee, Spasticity, Pyruvate Dehydrogenase Complex Deficiency (PDCD). It is also focused on the acquisition of approved prescription products and clinical development stage compounds. Soal partners with pharmaceutical and biotechnology companies and academia to conduct research and clinical trials. The company operates through offices in Ireland and Bermuda. Saol is headquartered in Roswell, Georgia, the US.
For a complete picture of Sodium dichloroacetate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
